A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
Inclusion Criteria:
Exclusion Criteria:
Topeka, Kansas 66606, United States
Lake Success, New York 11042, United States
Vancouver, British Columbia V5Z 1M9, Canada
Vancouver, British Columbia V6Z 2K5, Canada
Montreal, Quebec H4A 3J1, Canada
Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
Kiel, Schleswig-Holstein 24105, Germany
Bologna, Emilia-Romagna 40138, Italy
Otago, Otago 9016, New Zealand
Warsaw, Masovian Voivodeship 02-507, Poland
Lodz, Łódź Voivodeship 90-302, Poland
Ferrol, A Coruna 15405, Spain
Manchester, Manchester M13 9WL, United Kingdom